Katrina Pollock
MA MBBS MRCP DipGUM DipHIV DFSRH PhD
MRC Clinician Scientist in Vaccinology
- Chief investigator for the Lymph nodE single-cell Genomics AnCestrY and ageing (LEGACY) Network
- Chief and principal investigator for experimental medicine and first-in-human vaccine studies
- Honorary consultant in sexual health.
Human tissue based vaccine immunology.
Biography
Dr Katrina Pollock is an MRC Clinician Scientist in Vaccinology at the Oxford Vaccine Group, University of Oxford, Honorary Clinical Senior Lecturer in Vaccinology at the Department of Infectious Disease, Imperial College London, and Honorary Consultant in Sexual Health. She read medicine as an undergraduate at Newnham College, University of Cambridge, and Imperial College London before completing specialty training as a clinician scientist in genitourinary and HIV medicine, with a PhD and lectureship in immunology. Having led a series of first-in-human trials of novel vaccines including COVID-19 at Imperial College London, she received an award for substantial and exceptional achievement during the COVID-19 pandemic. Her work seeks to define tissue-based mechanisms of vaccine immunogenicity in diverse populations to leverage this for novel vaccine design. She is passionate about involving the public and participants at all stages, to lead innovative research that changes lives for the better.
Recent publications
-
A phase I double-blind trial investigating trachoma vaccine regimens using the Chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02)
Journal article
Pollock K., (2024), The Lancet Infectious Diseases
-
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.
Journal article
Thwaites RS. et al, (2023), Nat Commun, 14
-
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
Journal article
Liu Z. et al, (2023), J Crohns Colitis
-
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Journal article
Liu Z. et al, (2023), eClinicalMedicine, 64
-
Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.
Journal article
Khan M. et al, (2023), Open Forum Infect Dis, 10